Iguratimod May Hold Promise for Treating Autoimmune Disease
NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Natasha Yetman Tags: DMARDs & Immunosuppressives Drug Updates Autoimmune disease bone China iguratimod Source Type: research
More News: Arthritis | Autoimmune Disease | China Health | Japan Health | Rheumatoid Arthritis | Rheumatology